CAI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
263.7M
+22.0%
216.2M
-26.2%
292.9M
+35.1%
216.8M
+19.5%
181.4M
Cost of Revenue
84.1M
+12.4%
74.8M
+4.0%
72.0M
+3.8%
69.3M
+2.4%
67.7M
Gross Profit
179.6M
+27.1%
141.3M
-36.0%
220.9M
+49.8%
147.5M
+29.7%
113.7M
Operating Expenses
152.7M
+12.2%
136.1M
+2.7%
132.5M
+15.4%
114.9M
-12.8%
131.7M
R&D
32.4M
+3.3%
31.3M
-1.7%
31.8M
+47.3%
21.6M
-13.7%
25.0M
SG&A
120.3M
+14.9%
104.8M
+4.1%
100.7M
+8.0%
93.2M
-12.6%
106.6M
Operating Income
26.9M
+409.8%
5.3M
-94.0%
88.4M
+170.9%
32.6M
+281.5%
-17989000
EBITDA
33.5M
+223.4%
10.3M
-88.8%
92.7M
+147.1%
37.5M
+423.9%
-11580000
Net Income
-637000
-24.9%
-510000
-100.6%
82.0M
+236.9%
24.3M
+133.9%
-71790000
EPS (Basic)
$0.00
$0.00
-100.0%
$0.29
+222.2%
$0.09
+101.1%
$-7.97
EPS (Diluted)
$0.00
$0.00
-100.0%
$0.30
+275.0%
$0.08
+101.0%
$-7.97
Shares (Diluted)
282.9M
+0.1%
282.6M
+4.2%
271.1M
-8.8%
297.2M
+357.8%
64.9M
Caris Life Sciences (CAI) โ€” Financials